EGFR and non-small cell lung carcinoma: Taken together, these current limitations in targeting EGFR for long-term clinical benefit, plus the fact that effective therapies for NSCLC with mutation profiles typical for cigarette smoking are yet to be identified [31,62], highlight the urgent medical need to identify novel molecular targets to tackle NSCLC and other cancers.